SLE患者外周血造血干/祖细胞的检测及临床意义

目的 探讨SLE患者外周血CD34+造血干/祖细胞（HSC/HPC）数目与CD34膜表达的变化。方法 采用异硫氰酸荧光素标记抗体，以流式细胞仪检测30例SLE患者和14例正常人外周血CD34+ HSC/HPC，分析CD34+ HSC/HPC细胞占全部淋巴细胞的百分比和CD34平均荧光强度，并结合临床资料进行相关性分析。结果 活动期和稳定期SLE患者外周血CD34+ HSC/HPC细胞占淋巴细胞百分比分别为（0.15 ± 0.10）%和（0.09 ± 0.07）%，低于正常人对照组［（0.37 ± 0.17）%，F = 17.18，P < 0.01］，而活动期和稳定期SLE患者差异无统计学意义（t = 1.51，P > 0.05）；活动期SLE患者外周血CD34抗原的平均荧光强度为41.35 ± 19.24，高于正常人对照组（27.43 ± 7.57，F = 3.13，P < 0.05），而稳定期SLE患者与正常人对照组差异无统计学意义（F = 3.13，P > 0.05）。外周血CD34+ HSC/HPC细胞百分比与血清IgG水平呈负相关（r = -0.588，P < 0.01），与SLE疾病活动指数（SLEDAI）、补体、抗dsDNA抗体、抗C1q抗体、抗核小体抗体等无统计学相关性。结论 SLE患者外周血CD34+ HSC/HPC细胞数减少，并且CD34抗原表达增加，提示SLE患者HSC/HPC功能存在异常，可能参与SLE的发病。

Detection and clinical significance of peripheral blood hematopoietic stem/progenitor cells in patients with systemic lupus erythematosus (SLE)

Objective To measure the number of peripheral blood CD34+ hematopoietic stem/progenitor cells (HSC/HPCs) and membrane expression of CD34 on these cells in patients with SLE. Methods Lymphocytes were isolated from peripheral blood of 30 patients with SLE and 14 normal human controls. Flow cytometry using FITC-labeled antibodies was performed to determine the percentage of CD34+ HSC/HPCs and mean fluorescence intensity (MFI) of CD34 on these cells. Their correlation with clinical data was analyzed.Results The percentage of CD34+ HSC/HPCs in peripheral lymphocytes was (0.15 ± 0.10)% and (0.09 ±0.07)% in active and stable SLE patients, respectively, significantly lower than that in normal controls [(0.37 +0.17)%, F = 17.18, P ＜ 0.01], however, there was no significant difference between active and stable SLE patients (t = 1.51, P＞ 0.05). The MFI of CD34 was higher in active SLE patients than in the normal controls (41.35 ± 19.24 vs. 27.43 ± 7.57, F= 3.13, P ＜ 0.05), but no difference was observed between stable SLE patients and normal controls (F= 3.13, P ＞ 0.05). In patients with SLE, the percentage of CD34+ HSC/HPCs was negatively correlated with serum IgG levels (r = -0.588, P ＜ 0.01 ), but uncorrelated with SLE disease activity index (SLEDAI) or serum levels of complement, anti-dsDNA antibodies, anti-C1q antibodies, antinucleosome antibodies, etc. Conclusions The count of CD34+ HSC/HPCs is reduced while the MFI of CD34 antigen is elevated in SLE patients, hinting that there is a functional abnormality of HSC/HPCs in SLE patients, which may be involved in the pathogenesis of SLE.